Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 2Sarcoma, Kaposi 1Sarcoma 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Neurofibromatosis 1 1Neoplasm Metastasis 1Liposarcoma 1Leiomyosarcoma 1Glioma 1Colorectal Neoplasms 1Brain Neoplasms 1Acquired Immunodeficiency Syndrome 1

Interventions

Doxorubicin 7Radiotherapy 6Ifosfamide 5Specimen Handling 4Etoposide 3Biopsy 3cixutumumab 2Vincristine 2Radiation 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Epirubicin 2Dactinomycin 2Cyclophosphamide 2Chemotherapy, Adjuvant 2Carboplatin 2temsirolimus 1talimogene laherparepvec 1saracatinib 1romidepsin 1peposertib 1pembrolizumab 1pazopanib 1liposomal doxorubicin 1abemaciclib 1X-Rays 1Temozolomide 1Sorafenib 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Liposarcoma × abemaciclib × Clear all
NCT06498648 2026-05-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
74 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡